Is adagrasib clinically available in China?

Adagrasib (Adagrasib) is a drug targeting certain malignant tumors with specific gene mutations and is classified as a KRAS G12C inhibitor. This mutation is common in some common cancer types, including non-small cell lung cancer. The research and development of adagrasib is still in progress. It is understood that Mirati Therapeutics (Bristol-Myers Squibb) and Zai Lab (Zai Lab) have reached a cooperation to develop and commercialize adagrasib in Greater China. They have obtained the rights to develop and exclusively commercialize adagrasib in mainland China, Hong Kong, Macau and Taiwan, and may currently be in the clinical trial phase.

Adagrasiib is a prescription drug used to treat non-small cell lung cancer (NSCLC) in adults: patients whose tumors have spread to other parts of the body or cannot be removed by surgery, whose tumors have an abnormal KRAS G12C gene, and who have received at least one cancer treatment. Doctors will conduct tests to make sure adagrasib is suitable for patients. It is not yet clear whether adagrasib is safe and effective in children. KRAS produces a protein that, when mutated, like KRAS G12C, can trigger a domino effect that leads to cancer. Adagrasib is designed to target KRAS G12C to inhibit tumor growth.

Lung cancer is the most common cancer in China, and Bristol-Myers Squibb andZai Lab’s research and development goal is to make adagrasiib an important product in the growing lung cancer product portfolio. It is believed that in the near future, adagrasib will be available for sale in China, adding another treatment option for patients.